Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
March 17, 2022 07:15 ET
|
Resverlogix Corp
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary Arterial...
Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th
March 09, 2022 13:39 ET
|
Virtual Investor Conferences
CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global leader in the development of epigenetic therapeutics, today announced that Donald...
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
February 22, 2022 07:15 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) +...
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
February 17, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that the first Brazilian site has been initiated for its Phase 2b study to evaluate...
Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
January 31, 2022 08:00 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors. Dr....
Resverlogix 宣佈在加拿大開發具有前景的 2019 冠狀病毒病治療的第 2b 期測試開始患者招募和給藥
January 19, 2022 03:58 ET
|
Resverlogix Corp
艾省卡加利, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp.（以下簡稱「Resverlogix」）(TSX:RVX) 今天欣然宣佈，在埃德蒙頓阿爾伯塔大學醫院的研究中心進行第 2b 期研究已開始患者招募和給藥。試驗將評估 apabetalone 作為 2019 冠狀病毒病的潛在口服治療藥物的安全性與功效。 Apabetalone...
Resverlogix宣布在加拿大开发的一种有前景的新冠肺炎药物的2b期临床试验中开始患者招募和给药
January 19, 2022 03:58 ET
|
Resverlogix Corp
阿尔伯塔省卡尔加里, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp.（以下简称“Resverlogix”）（多伦多证券交易所股票代码： RVX）今天高兴地宣布，在埃德蒙顿阿尔伯塔大学医院一个临床中心进行的一项2b阶段研究已开始患者招募和给药。试验将对apabetalone作为新冠肺炎潜在口服药物的安全性和疗效进行评估。 ...
Resverlogix annonce le début du recrutement et du dosage des patients pour un essai de phase 2b d’un traitement prometteur contre la COVID-19 développé au Canada
January 18, 2022 11:10 ET
|
Resverlogix Corp
CALGARY, Alberta, 18 janv. 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (« Resverlogix ») (TSX:RVX) a annoncé aujourd’hui que le recrutement et le dosage des patients ont commencé dans le cadre d’une...
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
January 18, 2022 07:15 ET
|
Resverlogix Corp
CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study...
Resverlogix Announces Corporate Update Webcast and Conference Call
December 13, 2021 06:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that they will be hosting a corporate update webcast and conference call on Thursday,...